Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer.

The androgen receptor (AR) pathway is a key driver of neoplastic behaviour in the different stages of metastatic prostate cancer (mPCa). Targeting the AR therefore remains the cornerstone for mPCa treatment.